Twist Bioscience Corp. (TWST)
127.22
+0.37
(+0.29%)
USD |
NASDAQ |
Sep 11, 16:00
127.09
-0.13
(-0.10%)
After-Hours: 20:00
Twist Bioscience Enterprise Value : 7.900B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 7.900B |
| September 10, 2026 | 7.877B |
| September 09, 2026 | 7.794B |
| September 08, 2026 | 7.953B |
| September 04, 2026 | 7.743B |
| September 03, 2026 | 7.994B |
| September 02, 2026 | 8.137B |
| September 01, 2026 | 8.203B |
| August 31, 2026 | 8.638B |
| August 28, 2026 | 8.788B |
| August 27, 2026 | 9.522B |
| August 26, 2026 | 9.332B |
| August 25, 2026 | 9.417B |
| August 24, 2026 | 8.751B |
| August 21, 2026 | 9.051B |
| August 20, 2026 | 8.471B |
| August 19, 2026 | 8.851B |
| August 18, 2026 | 7.203B |
| August 17, 2026 | 7.724B |
| August 14, 2026 | 7.358B |
| August 13, 2026 | 7.779B |
| August 12, 2026 | 7.774B |
| August 11, 2026 | 7.643B |
| August 10, 2026 | 7.753B |
| August 07, 2026 | 7.176B |
| Date | Value |
|---|---|
| August 06, 2026 | 6.763B |
| August 05, 2026 | 7.135B |
| August 04, 2026 | 6.159B |
| August 03, 2026 | 6.261B |
| July 31, 2026 | 5.665B |
| July 30, 2026 | 5.651B |
| July 29, 2026 | 5.283B |
| July 28, 2026 | 5.477B |
| July 27, 2026 | 5.351B |
| July 24, 2026 | 5.584B |
| July 23, 2026 | 5.720B |
| July 22, 2026 | 5.831B |
| July 21, 2026 | 5.935B |
| July 20, 2026 | 5.408B |
| July 17, 2026 | 5.809B |
| July 16, 2026 | 5.644B |
| July 15, 2026 | 5.731B |
| July 14, 2026 | 5.726B |
| July 13, 2026 | 5.589B |
| July 10, 2026 | 5.607B |
| July 09, 2026 | 5.797B |
| July 08, 2026 | 5.529B |
| July 07, 2026 | 5.632B |
| July 06, 2026 | 6.190B |
| July 02, 2026 | 6.147B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.279B |
| Beam Therapeutics, Inc. | 1.572B |
| Absci Corp. | 1.211B |
| Prime Medicine, Inc. | 583.12M |
| Generate Biomedicines, Inc. | 1.622B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.05M |
| Revenue (Quarterly) | 118.38M |
| Total Expenses (Quarterly) | 153.43M |
| EPS Diluted (Quarterly) | -0.5617 |
| Gross Profit Margin (Quarterly) | 52.76% |
| Profit Margin (Quarterly) | -29.61% |
| Earnings Yield | -1.75% |
| Normalized Earnings Yield | -1.684 |